Study Finds Exenatide Not Beneficial for Parkinson Disease

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 7, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, Feb. 7, 2025 -- The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, according to a study published online Feb. 4 in The Lancet.

Nirosen Vijiaratnam, M.D., from the University College London Queen Square Institute of Neurology, and colleagues conducted a phase 3, multicenter trial at six research hospitals in the United Kingdom involving patients aged 25 to 80 years with a diagnosis of Parkinson disease who were randomly assigned to receive extended-release exenatide 2 mg by subcutaneous pen injection once per week over 96 weeks or visually identical placebo (97 patients in each group).

The analyses included 92 patients in the exenatide group and 96 in the placebo group with at least one follow-up visit. The researchers found that the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale part III score, off dopaminergic medication at 96 weeks, increased (worsened) by a mean of 5.7 and 4.5 points in the exenatide and placebo groups, respectively (adjusted coefficient for the effect of exenatide, 0.92; 95 percent confidence interval, −1.56 to 3.39; P = 0.47). Nine and 11 participants in the exenatide and placebo groups, respectively, had at least one serious adverse event.

"The results of this trial are discordant with previous laboratory and epidemiology data and previous trial results," the authors write. "We aim to do further post-hoc analyses to try and explain the reasons for this inconsistency."

Several authors disclosed ties to biopharmaceutical companies. AstraZeneca provided exenatide for the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-08 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords